Zou demonstrated that FAT10 contributed to bladder cancer development by promoting EGFR/AKT-mediated activation of HK2 [11], which suggested that FAT10 induced epithelial-mesenchymal transition and accelerated HCC cell metastasis by modulating the AKT/GSK3β pathway, thereby affecting the HCC prognosis [12]. Here, AKT1 is linked to urinary bladder carcinoma.